Clorox (CLX) has drawn fresh investor attention after appointing Chris Hyder as executive vice president and chief operating officer, and Nina Barton as chief growth & strategy officer, during a period of operational and cash flow pressures.
See our latest analysis for Clorox.
The leadership changes come as Clorox's share price has softened, with a 1-day share price return of 2.25% offering a brief rebound after a 90-day share price decline of 11.57% and a 1-year total shareholder return decline of 20.66%. This indicates that momentum has weakened over both shorter and longer horizons.
If this kind of corporate reset has you reassessing your watchlist, it may be a good time to widen your search using the Simply Wall St screener for 20 top founder-led companies
With Clorox stock down over the past year despite annual revenue of about US$6.8b and net income of roughly US$756m, plus an indicated intrinsic discount of around 42%, investors have to ask: is this a genuine value opportunity, or is the market already baking in future growth expectations?
Most Popular Narrative: 12% Undervalued
Clorox's most followed narrative sets a fair value of about $105.29 per share, compared with a last close of $92.64, which frames the current debate around the stock.
The full-scale implementation of a modern ERP system is expected to drive long-term operational efficiencies, improving supply chain visibility, speeding innovation cycles, and reducing structural costs. This should support margin expansion and sustained earnings growth once short-term transition noise normalizes.
Want to see what sits behind that fair value gap? The narrative leans on measured revenue growth, steady margins, and a future earnings multiple that has been carefully recalibrated. The tension between slower growth than the wider market and a higher required return is already baked in. The full story is in how those pieces fit together over the next few years.
Result: Fair Value of $105.29 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Clorox narrative also leans on assumptions that could be tested if sluggish category growth persists or if price competition and discounting continue to squeeze margins.
Find out about the key risks to this Clorox narrative.
Next Steps
If the mixed signals around Clorox have you unsure, do not wait for consensus to form; review the full risk and reward balance in the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Clorox?
If Clorox has sharpened your focus on quality and valuation, now is a smart moment to scan wider and line up a few more candidates on your radar.
- Spot potential value standouts before they move by checking the Simply Wall St screener for 44 high quality undervalued stocks
- Prioritise resilience and sleep-at-night holdings with the Simply Wall St screener for 67 resilient stocks with low risk scores
- Hunt for future leaders hiding in plain sight using the Simply Wall St screener for screener containing 19 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com